Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Cogent Biosciences Secures Massive $200M Funding to Accelerate Bezuclastinib Development - Stock Titan

Cogent Biosciences Secures Massive $200M Funding to Accelerate Bezuclastinib Development  Stock Titan

Cogent Biosciences Secures Massive $200M Funding to Accelerate Bezuclastinib Development - Stock Titan

Click here to get full coverage on COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - Zacks Investment Research

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success  Zacks Investment Research

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - Zacks Investment Research

Click here to get full coverage on Cogent Biosciences, Inc. Announces Underwritten Public Offering of $150 Million in Common Stock - Quiver Quantitative

Cogent Biosciences, Inc. Announces Underwritten Public Offering of $150 Million in Common Stock  Quiver Quantitative

Cogent Biosciences, Inc. Announces Underwritten Public Offering of $150 Million in Common Stock - Quiver Quantitative

Click here to get full coverage on Cogent Biosciences’ 29% Surge: Unraveling the Mystery Behind the Spike - AInvest

Cogent Biosciences’ 29% Surge: Unraveling the Mystery Behind the Spike  AInvest

Cogent Biosciences’ 29% Surge: Unraveling the Mystery Behind the Spike - AInvest

Click here to get full coverage on Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock - TradingView

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock  TradingView

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock - TradingView

Click here to get full coverage on Cogent Biosciences Raises $150M in Stock Offering to Advance Precision Therapy Commercialization - Stock Titan

Cogent Biosciences Raises $150M in Stock Offering to Advance Precision Therapy Commercialization  Stock Titan

Cogent Biosciences Raises $150M in Stock Offering to Advance Precision Therapy Commercialization - Stock Titan

Click here to get full coverage on Cogent surges as bezuclastinib meets key goal in phase 2 mastocytosis trial - MSN

Cogent surges as bezuclastinib meets key goal in phase 2 mastocytosis trial  MSN

Cogent surges as bezuclastinib meets key goal in phase 2 mastocytosis trial - MSN

Click here to get full coverage on Why Is Cogent Biosciences Stock Soaring On Tuesday? - Cogent Biosciences (NASDAQ:COGT) - Benzinga

Why Is Cogent Biosciences Stock Soaring On Tuesday? - Cogent Biosciences (NASDAQ:COGT)  Benzinga

Why Is Cogent Biosciences Stock Soaring On Tuesday? - Cogent Biosciences (NASDAQ:COGT) - Benzinga

Click here to get full coverage on Noteworthy Monday Option Activity: PRME, ELF, COGT - Nasdaq

Noteworthy Monday Option Activity: PRME, ELF, COGT  Nasdaq

Noteworthy Monday Option Activity: PRME, ELF, COGT - Nasdaq

Click here to get full coverage on Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now - Yahoo Finance

Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now  Yahoo Finance

Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now - Yahoo Finance

Click here to get full coverage on Cogent Biosciences: Analyzing the Recent Leap - StocksToTrade

Cogent Biosciences: Analyzing the Recent Leap  StocksToTrade

Cogent Biosciences: Analyzing the Recent Leap - StocksToTrade

Click here to get full coverage on Cogent Biosciences price target raised to $9 from $7 at Baird - TipRanks

Cogent Biosciences price target raised to $9 from $7 at Baird  TipRanks

Cogent Biosciences price target raised to $9 from $7 at Baird - TipRanks

Click here to get full coverage on Cogent Biosciences Soars 26.5%: Unraveling the Mystery Behind the Surge - AInvest

Cogent Biosciences Soars 26.5%: Unraveling the Mystery Behind the Surge  AInvest

Cogent Biosciences Soars 26.5%: Unraveling the Mystery Behind the Surge - AInvest

Click here to get full coverage on Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance

Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds?  Yahoo Finance

Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance

Click here to get full coverage on Cogent Biosciences Announces Positive SUMMIT Trial Results - TipRanks

Cogent Biosciences Announces Positive SUMMIT Trial Results  TipRanks

Cogent Biosciences Announces Positive SUMMIT Trial Results - TipRanks

Click here to get full coverage on Major Breakthrough: New Drug Shows Unprecedented 87% Success Rate in Rare Disease Treatment Trial Results - Stock Titan

Major Breakthrough: New Drug Shows Unprecedented 87% Success Rate in Rare Disease Treatment Trial Results  Stock Titan

Major Breakthrough: New Drug Shows Unprecedented 87% Success Rate in Rare Disease Treatment Trial Results - Stock Titan

Click here to get full coverage on Cogent Biosciences Surges 32.5%—What’s Driving the Spike? - AInvest

Cogent Biosciences Surges 32.5%—What’s Driving the Spike?  AInvest

Cogent Biosciences Surges 32.5%—What’s Driving the Spike? - AInvest

Click here to get full coverage on Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts - Yahoo Finance

Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts  Yahoo Finance

Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts - Yahoo Finance

Click here to get full coverage on Cogent Biosciences Lands Massive $400M Financing Deal as 3 Pivotal Trial Results Loom in 2025 - Stock Titan

Cogent Biosciences Lands Massive $400M Financing Deal as 3 Pivotal Trial Results Loom in 2025  Stock Titan

Cogent Biosciences Lands Massive $400M Financing Deal as 3 Pivotal Trial Results Loom in 2025 - Stock Titan

Click here to get full coverage on Cogent Biosciences Reveals Latest Precision Therapy Progress Plus New Employee Stock Options - Stock Titan

Cogent Biosciences Reveals Latest Precision Therapy Progress Plus New Employee Stock Options  Stock Titan

Cogent Biosciences Reveals Latest Precision Therapy Progress Plus New Employee Stock Options - Stock Titan

Click here to get full coverage on Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Yahoo Finance

Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential?  Yahoo Finance

Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Yahoo Finance

Click here to get full coverage on Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing - GlobeNewswire

Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing  GlobeNewswire

Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing - GlobeNewswire

Click here to get full coverage on We're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn Rate - Yahoo Finance

We're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn Rate  Yahoo Finance

We're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn Rate - Yahoo Finance

Click here to get full coverage on Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? - Nasdaq

Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now?  Nasdaq

Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? - Nasdaq

Click here to get full coverage on Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade - Nasdaq

Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade  Nasdaq

Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade - Nasdaq

Click here to get full coverage on Cogent Biosciences’ Bold Move: Can It Boost Stock? - timothysykes.com

Cogent Biosciences’ Bold Move: Can It Boost Stock?  timothysykes.com

Cogent Biosciences’ Bold Move: Can It Boost Stock? - timothysykes.com

Click here to get full coverage on Cogent announces statistical significance across all endpoints from SUMMIT trial - TipRanks

Cogent announces statistical significance across all endpoints from SUMMIT trial  TipRanks

Cogent announces statistical significance across all endpoints from SUMMIT trial - TipRanks

Click here to get full coverage on Cogent Biosciences Gears Up for 3 Major Clinical Trial Readouts in 2025, Maintains Strong $245M Cash Reserve - Stock Titan

Cogent Biosciences Gears Up for 3 Major Clinical Trial Readouts in 2025, Maintains Strong $245M Cash Reserve  Stock Titan

Cogent Biosciences Gears Up for 3 Major Clinical Trial Readouts in 2025, Maintains Strong $245M Cash Reserve - Stock Titan

Click here to get full coverage on Breakthrough: Cogent's Cancer Drug Achieves 90% Tumor Inhibition, Plus 3 More Pipeline Advances - Stock Titan

Breakthrough: Cogent's Cancer Drug Achieves 90% Tumor Inhibition, Plus 3 More Pipeline Advances  Stock Titan

Breakthrough: Cogent's Cancer Drug Achieves 90% Tumor Inhibition, Plus 3 More Pipeline Advances - Stock Titan

Click here to get full coverage on Cogent Biosciences stock falls on $150 million share offering By Investing.com - Investing.com UK

Cogent Biosciences stock falls on $150 million share offering By Investing.com  Investing.com UK

Cogent Biosciences stock falls on $150 million share offering By Investing.com - Investing.com UK

Click here to get full coverage on This Cogent Biosciences Insider Increased Their Holding By 2,085% Last Year - simplywall.st

This Cogent Biosciences Insider Increased Their Holding By 2,085% Last Year  simplywall.st

This Cogent Biosciences Insider Increased Their Holding By 2,085% Last Year - simplywall.st

Click here to get full coverage on (COGT) Investment Analysis - news.stocktradersdaily.com

(COGT) Investment Analysis  news.stocktradersdaily.com

(COGT) Investment Analysis - news.stocktradersdaily.com

Click here to get full coverage on Cogent Biosciences Reports First Quarter 2025 Financial Results - GlobeNewswire

Cogent Biosciences Reports First Quarter 2025 Financial Results  GlobeNewswire

Cogent Biosciences Reports First Quarter 2025 Financial Results - GlobeNewswire

Click here to get full coverage on Cogent Biosciences (COGT) Maintains 'Buy' Rating with Adjusted Price Target | COGT Stock News - GuruFocus

Cogent Biosciences (COGT) Maintains 'Buy' Rating with Adjusted Price Target | COGT Stock News  GuruFocus

Cogent Biosciences (COGT) Maintains 'Buy' Rating with Adjusted Price Target | COGT Stock News - GuruFocus

Click here to get full coverage on Cogent: Several 2025 Readouts On Deck With Bezuclastinib Advancement - Seeking Alpha

Cogent: Several 2025 Readouts On Deck With Bezuclastinib Advancement  Seeking Alpha

Cogent: Several 2025 Readouts On Deck With Bezuclastinib Advancement - Seeking Alpha

Click here to get full coverage on Noteworthy Thursday Option Activity: LLY, CVNA, COGT - Nasdaq

Noteworthy Thursday Option Activity: LLY, CVNA, COGT  Nasdaq

Noteworthy Thursday Option Activity: LLY, CVNA, COGT - Nasdaq

Click here to get full coverage on Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference - GlobeNewswire

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference  GlobeNewswire

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference - GlobeNewswire

Click here to get full coverage on Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Adv - GuruFocus

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Adv  GuruFocus

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Adv - GuruFocus

Click here to get full coverage on Cogent Biosciences Approves Officer Exculpation Amendment - TipRanks

Cogent Biosciences Approves Officer Exculpation Amendment  TipRanks

Cogent Biosciences Approves Officer Exculpation Amendment - TipRanks

Click here to get full coverage on Cogent Biosciences stock falls on $150 million share offering - Investing.com India

Cogent Biosciences stock falls on $150 million share offering  Investing.com India

Cogent Biosciences stock falls on $150 million share offering - Investing.com India

Click here to get full coverage on Cogent Eyes The SUMMIT As It Awaits Three Data Readouts Of Bezuclastinib - RTTNews

Cogent Eyes The SUMMIT As It Awaits Three Data Readouts Of Bezuclastinib  RTTNews

Cogent Eyes The SUMMIT As It Awaits Three Data Readouts Of Bezuclastinib - RTTNews

Click here to get full coverage on Cogent stock price target raised to $18 by Leerink on positive trial data - Investing.com UK

Cogent stock price target raised to $18 by Leerink on positive trial data  Investing.com UK

Cogent stock price target raised to $18 by Leerink on positive trial data - Investing.com UK

Click here to get full coverage on Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results  GlobeNewswire

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Click here to get full coverage on Cogent Biosciences stock surges after positive trial results By Investing.com - Investing.com UK

Cogent Biosciences stock surges after positive trial results By Investing.com  Investing.com UK

Cogent Biosciences stock surges after positive trial results By Investing.com - Investing.com UK

Click here to get full coverage on Jefferies raises Cogent price target to $28 on positive SUMMIT data By Investing.com - Investing.com South Africa

Jefferies raises Cogent price target to $28 on positive SUMMIT data By Investing.com  Investing.com South Africa

Jefferies raises Cogent price target to $28 on positive SUMMIT data By Investing.com - Investing.com South Africa

Click here to get full coverage on Citi adds ‘upside 30-day catalyst watch’ on Cogent Biosciences - TipRanks

Citi adds ‘upside 30-day catalyst watch’ on Cogent Biosciences  TipRanks

Citi adds ‘upside 30-day catalyst watch’ on Cogent Biosciences - TipRanks

Click here to get full coverage on Cogent Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Cogent Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary  TradingView

Cogent Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Click here to get full coverage on Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewswire

Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting  GlobeNewswire

Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewswire

Click here to get full coverage on Jefferies raises Cogent price target to $28 on positive SUMMIT data - Investing.com India

Jefferies raises Cogent price target to $28 on positive SUMMIT data  Investing.com India

Jefferies raises Cogent price target to $28 on positive SUMMIT data - Investing.com India

Click here to get full coverage on Cogent Biosciences, Inc. Unveils Preclinical Data from Four Pipeline Programs at AACR 2025 Annual Meeting - Nasdaq

Cogent Biosciences, Inc. Unveils Preclinical Data from Four Pipeline Programs at AACR 2025 Annual Meeting  Nasdaq

Cogent Biosciences, Inc. Unveils Preclinical Data from Four Pipeline Programs at AACR 2025 Annual Meeting - Nasdaq

Click here to get full coverage on Cogent shares price target cut to $12 by H.C. Wainwright - Investing.com

Cogent shares price target cut to $12 by H.C. Wainwright  Investing.com

Cogent shares price target cut to $12 by H.C. Wainwright - Investing.com

Click here to get full coverage on Piper Sandler maintains Cogent stock rating ahead of pivotal trial data - Investing.com India

Piper Sandler maintains Cogent stock rating ahead of pivotal trial data  Investing.com India

Piper Sandler maintains Cogent stock rating ahead of pivotal trial data - Investing.com India

Click here to get full coverage on Cogent Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference - Quiver Quantitative

Cogent Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference  Quiver Quantitative

Cogent Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference - Quiver Quantitative

Click here to get full coverage on Citi maintains buy rating on Cogent stock ahead of trial results By Investing.com - Investing.com South Africa

Citi maintains buy rating on Cogent stock ahead of trial results By Investing.com  Investing.com South Africa

Citi maintains buy rating on Cogent stock ahead of trial results By Investing.com - Investing.com South Africa

Click here to get full coverage on Cogent Biosciences Announces Bezuclastinib Poster in - GlobeNewswire

Cogent Biosciences Announces Bezuclastinib Poster in  GlobeNewswire

Cogent Biosciences Inc (COGT)

Price Chart

Key Statistics

Technicals

About COGT

Latest News

Cogent Biosciences Secures Massive $200M Funding to Accelerate Bezuclastinib Development - Stock Titan

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - Zacks Investment Research

Cogent Biosciences, Inc. Announces Underwritten Public Offering of $150 Million in Common Stock - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers